1 / 36

Personalizing Lipid Management: Statin Treatment Considerations in Patients With HIV

Personalizing Lipid Management: Statin Treatment Considerations in Patients With HIV. HIV-AIDS and CHD Risk. MI Rates Are Higher in HIV Patients Than in Uninfected Individuals. Dyslipidemia in HIV. HAART Lipid Effects. HAART Lipid Effects (cont).

gage-myers
Download Presentation

Personalizing Lipid Management: Statin Treatment Considerations in Patients With HIV

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Personalizing Lipid Management: Statin Treatment Considerations in Patients With HIV

  2. HIV-AIDS and CHD Risk

  3. MI Rates Are Higher in HIV Patients Than in Uninfected Individuals

  4. Dyslipidemia in HIV

  5. HAART Lipid Effects

  6. HAART Lipid Effects (cont)

  7. Recent FDA Label Changes for Statin Combination Rx With PIs

  8. Switching HAART to Improve Dyslipidemia in Those With HIV

  9. 34-Year-Old HIV-Infected Man

  10. 34-Year-Old HIV-Infected Man (cont)

  11. 34-Year-Old HIV-Infected Man: Medications

  12. The Statin Armamentarium: Individual Metabolism Characteristics

  13. Coadministering Statins With Protease Inhibitors: Dose Limitations

  14. 38-Year-Old HIV-Infected Man

  15. 38-Year-Old HIV-Infected Man (cont)

  16. D:A:D Study: Observed and Predicted Rates of MI by Duration of CART in HIV-Infected Patients

  17. Lipid Effects of Different Boosted PI Regimens

  18. STARTMRK: Effect of Raltegravir vs Efavirenz on Lipid Parameters at 96 Weeks

  19. MERIT Substudy: Effect of Maraviroc vs Efavirenz on Lipid Parameters at 96 Weeks

  20. HIV-Infected Patients Have Elevated Levels of Inflammation Even With ART

  21. NCEP ATP III LDL-C Goals Are Reasonable in HIV-Infected Patients

  22. The DAD Study: Risk Factors for MI in HIV-Infected Patients on ART

  23. Smoking Status in Patients With HIV/AIDS

  24. The Statin Class: Approximate LDL-C Lowering Efficacy at Different Doses

  25. In Theory, HAART Interactions With Rosuvastatin Should Be Limited, However…

  26. Statin Dose Limitations in HIV-Infected Patients on Protease Inhibitors

  27. Effect of Statin Therapy on Reducing the Risk of Serious Non-AIDS-Defining Events and Non-Accidental Death: ACTG ALLRT Cohort

  28. Program Summary

More Related